# Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect

> **NCT01072162** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 40 (actual)

## Conditions studied

- Purpura, Thrombocytopaenic, Idiopathic

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** Eltrombopag

## Key facts

- **NCT ID:** NCT01072162
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01-12
- **Primary completion:** 2010-04-07
- **Final completion:** 2010-04-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01072162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01072162, "Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation and Food Effect". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01072162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*